Search results for "Blood Grouping and Crossmatching"

showing 4 items of 4 documents

Weak D and partial D: our experience in daily activity

2011

Rh-Hr Blood-Group SystemBlood Grouping and CrossmatchingGene Expression RegulationGenotyping TechniquesHumansLettersBlood weak D partial DErythrocyte TransfusionPolymerase Chain ReactionAlleles
researchProduct

A NEW PCR-BASED TYPING OF THE RODGERS AND CHIDO ANTIGENIC DETERMINANTS OF THE FOURTH COMPONENT OF HUMAN COMPLEMEMT

1994

The Rodgers (Rg) and Chido (Ch) blood groups are antigenic determinants of the fourth component of human complement C4. They are associated with the two isotypes of C4, C4A and C4B, respectively. They serve as markers to distinguish C4A from C4B as well as for the definition of subtypes of common and rare allotypes. As an alternative to the serological typing method using human alloantisera, a PCR typing procedure with sequence-specific primers (PCR-SSP) was designed. The method was tested on selected DNA samples from individuals with well-defined C4 allotypes. No false-positive or false-negative typing results were obtained and all the determinant combinations could be distinguished. The P…

GeneticsAntigenicityGenotypeImmunologyC4ABiologyPolymerase Chain ReactionIsotypelaw.inventionBlood Grouping and CrossmatchinglawGenotypeBlood Group AntigensComplement C4bGeneticsHumansTypingAlleleGenotypingAllelesPolymerase chain reactionDNA PrimersEuropean Journal of Immunogenetics
researchProduct

Serologic and molecular characterization of weak D type 29

2017

MaleDNA ComplementaryTunisiaImmunologyBlood Donors030204 cardiovascular system & hematologyBiologyPolymorphism Single NucleotideWhite PeopleArticleSerology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhylogeneticsGermanyHumansImmunology and AllergyAlleleAllelesPhylogenyGeneticsRh-Hr Blood-Group SystemExonsHematologyBlood Grouping and CrossmatchingHaplotypeschemistryChromosomes Human Pair 1FemaleDNA030215 immunologyTransfusion
researchProduct

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies

2018

Daratumumab has proven to be highly efficacious for relapsed and refractory multiple myeloma (MM) and has recently been approved in the frontline setting for MM patients ineligible for transplantation. In the future, expanded indications are possible for daratumumab and other anti-CD38 monoclonal antibodies in development. For several years, it has been recognized that these therapies interfere with blood bank testing by binding to CD38 on red blood cells and causing panagglutination on the Indirect Antiglobulin Test. This can lead to redundant testing and significant delays in patient care. Given the anticipated increase in utilization of anti-CD38 monoclonal antibodies, as well as the tra…

lcsh:Immunologic diseases. Allergymedicine.medical_specialtyErythrocytesBlood transfusionmedicine.drug_classmedicine.medical_treatmentImmunologyAntineoplastic AgentsReview030204 cardiovascular system & hematologyCD38Monoclonal antibody03 medical and health sciences0302 clinical medicinemedicineHumansImmunology and AllergyBlood TransfusionDiagnostic ErrorsIntensive care medicinetransfusionIsatuximabbusiness.industryAntibodies MonoclonalDaratumumabdaratumumabADP-ribosyl Cyclase 1TransplantationCoombs TestBlood Grouping and Crossmatchingmonoclonal antibodyPractice Guidelines as TopicIndirect Antiglobulin Testlcsh:RC581-607Multiple MyelomabusinessCD38Blood bankProtein Bindingisatuximab030215 immunologyFrontiers in Immunology
researchProduct